Respiratory Syncytial Virus Antibodies, Vaccines & Antivirals 2017; New Report Launched

This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumb), a candidate for biosimilar conversion in the near future.

RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

RSV Antibodies:

• Palivizumab Biosuperiors
• Palivizumab Biosimilars

RSV Antivirals:

• Small Molecule Therapeuticss
• Other RSV Therapeutics

RSV Vaccines:

• Live-Attenuated & Whole-Inactivated RSV Vaccines
• Virus-Like Particle (VLP) RSV Vaccines
• Subunit RSV Vaccines
• DNA-/RNA-Based RSV Vaccines

Please visit this link for more details: http://mrr.cm/Umu

Related Reports;

Competitor Analysis - Kallikrein Inhibitors 2017 - Visit at - http://mrr.cm/UmL

Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins - Visit at - http://mrr.cm/Umb

Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars - Visit at - http://mrr.cm/UmE

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare